EarningsQ2 2026 Earnings Report
MX:BRKR Q2 2026 EPS Results
Actual EPS$8.29
Consensus EPS$6.51
Beat/MissBeat by +$1.78
One Year Ago EPS$5.41
MX:BRKR Q2 2026 Revenue Results
Actual Revenue$14.18B
Expected Revenue$14.44B
Beat/MissMissed by -$254.93M
YoY Revenue Growth+5.15%
Earnings Announcement Details
QuarterQ2 2026
Date08/04/2026
TimeBefore Open
Conference CallTuesday, August 4, 2026
MX:BRKR Upcoming Earnings
Bruker's next earnings date is estimated for October 29, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
MX:BRKR Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call showed material operational and financial progress — notably a return to organic growth in Q2, substantial margin expansion, double-digit non-GAAP EPS growth, strong deep-tech and semiconductor bookings, and confirmed cost-savings execution and year guidance. However, material lowlights included a $135M goodwill impairment leading to a GAAP loss, lingering weakness in U.S. academic/government spending, regional softness in China and APAC, timing-related revenue recognition delays from longer lead-time deep tech orders, and FX/tariff headwinds. On balance the positive momentum in bookings, margins, cash flow and cost savings, along with maintained FY guidance, outweigh the notable one-time impairment and near-term timing/currency headwinds.Company Guidance
Returned to Organic Revenue Growth in Q2
Reported Q2 2026 revenue of $838.5M, up 5.2% year-over-year; organic revenue growth of 2.8% in Q2 (3.4% excluding U.S. tariff refunds). Acquisitions contributed 1.5% to revenue and constant currency growth was 4.3%.
Scientific Instruments Bookings Strength
Scientific Instruments achieved 10% organic bookings growth year-over-year in Q2 and the segment has recorded a book-to-bill above 1.0 for four consecutive quarters, signaling improving demand and backlog health.
Biopharma and Life-Science Order Momentum
Organic bookings in biopharma grew more than 20% in Q2, driven by demand for NMR, x-ray and mass spectrometry solutions; European and China academic/medical research bookings were up strongly.
Deep Tech and Semiconductor Metrology Outperformance
Deep tech tools (semiconductor metrology, energy research, security detection) delivered exceptional order growth: semiconductor metrology >30% organic order growth H1 and >15% organic revenue growth H1; semi and energy research orders were >50% organic YoY in Q2; semiconductor metrology business has about a 30% EBIT margin.
Margin Expansion and EPS Growth on Non-GAAP Basis
Q2 non-GAAP gross margin improved to 52.1% (up ~350 bps YoY) and non-GAAP operating margin to 14.1% (up ~510 bps YoY). Q2 non-GAAP diluted EPS was $0.49, up 53% from $0.32 year-over-year.
Material Cost-Savings Progress
Company is on track to deliver $140M of annualized cost savings in 2026, realized approximately $30M of cost savings in Q2 alone, and expects an additional ~$20M of cost reductions in FY2027 tied to the new operating structure.
Improved Cash Flow and Leverage
Operating cash flow improved by $50M year-over-year in Q2 and free cash flow improved approx. $43M year-over-year; net leverage ratio improved to 2.8x as of June 30, 2026.
Fiscal 2026 Guidance Retained with Margin Upside
Company reiterated FY2026 outlook: reported revenue $3.54B–$3.57B (3%–4% reported growth), organic revenue growth 1%–2%, non-GAAP operating margin expansion of 250–300 bps, and non-GAAP EPS $2.10–$2.15 (15%–17% growth).
Q4 Expected Strong Sequential and Year-Over-Year Improvement
Management expects Q3 organic revenue to be roughly flat to slightly up (with ~$20M of previously planned Q3 revenue shifting to Q4) and anticipates meaningful sequential and YoY increases in organic revenue, operating margin and EPS in Q4 driven by higher volume and favorable mix.
Organizational Realignment to Support Cross-Workflow Offerings
Effective July 1, Bruker reorganized into four groups (Biosystems, Nano, BMID, BEST) to align around connected workflows and drive additional agility and targeted investment; management expects this to deliver structural benefits and incremental cost reductions.
MX:BRKR Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed